{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Well-differentiated+Neuroendocrine+Tumors", "query": { "condition": "Advanced Well-differentiated Neuroendocrine Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Well-differentiated+Neuroendocrine+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T20:04:35.776Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GEP-NET", "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Tumor Disease", "Neuroendocrine Tumors", "Carcinoid", "Carcinoid Tumor", "Pancreatic NET" ], "interventions": [ { "name": "RYZ101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Lanreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2022-03-24", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477576" }, { "nct_id": "NCT00118248", "title": "Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2004-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118248" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT05538130", "title": "A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Glioma", "Thyroid Cancer", "Non-Small Cell Lung Cancer", "Malignant Neoplasms", "Brain Neoplasms", "Advanced or Metastatic Solid Tumors", "HGG", "LGG", "Low Grade Glioma", "High Grade Glioma", "Differentiated Thyroid Cancer", "NSCLC (Non-small Cell Lung Cancer)" ], "interventions": [ { "name": "PF-07799544", "type": "DRUG" }, { "name": "PF-07799933", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 148, "start_date": "2022-11-30", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538130" }, { "nct_id": "NCT06784752", "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Somatostatin Receptor Positive (SSTR+)", "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)" ], "interventions": [ { "name": "[177Lu]Lu-DOTA-TATE", "type": "RADIATION" }, { "name": "Octreotide LAR", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 240, "start_date": "2025-05-30", "completion_date": "2034-01-23", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784752" }, { "nct_id": "NCT03070301", "title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-02-27", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070301" }, { "nct_id": "NCT02955069", "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Well-differentiated Non-functional NET of Thoracic Origin", "Well-differentiated Non-functional NET of Gastrointestinal Origin", "Well-differentiated Non-functional NET of Pancreatic Origin", "Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2017-02-14", "completion_date": "2020-05-13", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 7, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955069" }, { "nct_id": "NCT05475210", "title": "177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-DOTA-EB-TATE", "type": "DRUG" }, { "name": "Amino Acid Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Molecular Targeting Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2022-06-18", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05475210" }, { "nct_id": "NCT05247905", "title": "Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Unresectable Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-02-16", "completion_date": "2033-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 171, "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05247905" }, { "nct_id": "NCT00654238", "title": "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Differentiated Thyroid Cancer", "Metastatic Poorly Differentiated Thyroid Cancer", "Metastatic Anaplastic Thyroid Cancer", "Metastatic Medullary Thyroid Cancer" ], "interventions": [ { "name": "sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2006-02", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-09-24T20:04:35.776Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654238" } ] }